FDA Raises Concerns Over Longeveron's HLHS Trial Endpoint

Event summary

  • Longeveron held a Type C meeting with the FDA in late March 2026 regarding its ELPIS II Phase 2b trial for Hypoplastic Left Heart Syndrome (HLHS).
  • The FDA deemed the primary endpoint (right ventricle ejection fraction) insufficient to demonstrate efficacy, removing the trial's pivotal status.
  • Top-line results from the ELPIS II trial are expected in August 2026, with the FDA open to further discussions post-readout.
  • Longeveron is preparing a Sponsor Statistical Analysis Plan (SAP) with a composite primary endpoint for FDA review.

The big picture

Longeveron's setback with the FDA highlights the challenges of developing therapies for rare pediatric diseases, where regulatory expectations can shift mid-trial. The focus on objective measures like mortality and transplant-free survival reflects broader trends in regulatory stringency for high-risk patient populations. The outcome of this trial will be critical for Longeveron's pipeline and its ability to leverage FDA designations like Orphan Drug and Rare Pediatric Disease for future approvals.

What we're watching

Regulatory Alignment
Whether Longeveron can secure FDA agreement on a composite primary endpoint post-trial to support a Biologics License Application (BLA).
Trial Outcomes
The impact of the FDA's focus on objective measures like all-cause mortality and cardiac transplant-free survival on the trial's success.
Strategic Pivot
How Longeveron will adapt its regulatory strategy if the ELPIS II trial does not meet the FDA's revised expectations.

Related topics

Biotechnology